Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Oct 23 (Reuters) - Cumberland Pharmaceuticals Inc. CPIX.O:
CUMBERLAND PHARMACEUTICALS ANNOUNCES ASSIST-SSC TRIAL TOP-LINE RESULTS
CUMBERLAND PHARMACEUTICALS - IFETROBAN DEMONSTRATES SAFETY AND TOLERABILITY IN SYSTEMIC SCLEROSIS PATIENTS
CUMBERLAND PHARMACEUTICALS - IFETROBAN WELL TOLERATED; MOST GI ADVERSE EVENTS WERE MILD AND RESOLVED
CUMBERLAND PHARMACEUTICALS - NO SERIOUS ADVERSE EVENT RELATED TO IFETROBAN DURING 12-MONTH TREATMENT PERIOD
CUMBERLAND PHARMACEUTICALS - MODEST INCREASE IN MILD BLEEDING-RELATED ADVERSE EVENTS WITH IFETROBAN
Further company coverage: CPIX.O